Skip to content

Clinical observation study of Trans-PRK combined with monovision to correct presbyopia and myopia

Clinical observation study of Trans-PRK combined with monovision to correct presbyopia and myopia

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2100049534
Enrollment
Unknown
Registered
2021-08-02
Start date
2021-08-01
Completion date
Unknown
Last updated
2022-04-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Refractive error

Interventions

Trans-PRK combined with monovision group:Trans-PRK operation method
FS-LASIK combined with monovision group:FS-LASIK operation method

Sponsors

Tianjin Medical University Eye Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
40 Years to 60 Years

Inclusion criteria

Inclusion criteria: 1. Age >=40 years old; 2. The refractive status has been stable for more than 2 years; 3. Stop wearing soft contact lenses for more than 1 week; 4. The degree of spherical lens is 0D; 5. The lens is basically transparent.

Exclusion criteria

Exclusion criteria: 1. The whole body suffers from connective tissue diseases and autoimmune diseases; 2. Keratoconus or contusion keratoconus confirmed by corneal topography; 3. Active inflammation and infection of the eye or eye appendages; 4. Postoperative corneal stromal bed thickness is less than 250um; 5. Recently received other eye surgery, history of eye trauma, corneal disease and other eye diseases (including cataract, glaucoma, age-related macular degeneration, diabetic retinopathy, etc.).

Design outcomes

Primary

MeasureTime frame
vision;Corneal topography;Dual-channel visual quality analysis system;Contrast sensitivity;Binocular stereopsis;Visual function;

Countries

China

Contacts

Public ContactQi Yuanyuan

Tianjin Medical University Eye Hospital

qy890110@sina.com+86 22 86428803

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026